Aerosolized Antimicrobial Therapy in Acutely Ill Patients
Corresponding Author
G. Christopher Wood Pharm.D.
Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis, Memphis, Tennessee
Department of Clinical Pharmacy, University of Tennessee, Memphis, 26 South Dunlap, Suite 202, Memphis, TN 38163Search for more papers by this authorBradley A. Boucher Pharm.D., FCCP
Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis, Memphis, Tennessee
Search for more papers by this authorCorresponding Author
G. Christopher Wood Pharm.D.
Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis, Memphis, Tennessee
Department of Clinical Pharmacy, University of Tennessee, Memphis, 26 South Dunlap, Suite 202, Memphis, TN 38163Search for more papers by this authorBradley A. Boucher Pharm.D., FCCP
Department of Clinical Pharmacy, College of Pharmacy, The University of Tennessee, Memphis, Memphis, Tennessee
Search for more papers by this authorAbstract
Recent data are sparking renewed interest in therapy with aerosolized antimicrobials in critically ill patients as well as other populations such as those with neutropenia, human immunodeficiency virus infection, and cystic fibrosis. Pneumonia is a common complication in these patients and is associated with substantial morbidity and increased mortality. Clinical trials evaluated aerosolized antimicrobials for the prevention and treatment of pneumonia in hospitalized patients. In addition, factors that affect the pulmonary deposition of aerosolized drugs in mechanically ventilated patients were identified.
References
- 1 Palmer LB, Smaldone GC, Simon SR, et al. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998; 26(1): 31–9.
- 2 Itokazu GS, Weinstein RA. Aerosolized antimicrobials: another look [editorial]. Crit Care Med 1998; 26(1); 5–6.
- 3 Fink MP, Snydman DR, Neiderman MS, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38: 547–57.
- 4 Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585–90.
- 5 Klastersky J., Huysmans E., Weerts D., et al. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 1974; 65: 650–4.
- 6 Odio W., Van Laer E., Klastersky J.. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol 1975; 15: 518–24.
- 7 Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis 1987; 136: 1445–9.
- 8 Montgomery BA, Debs RJ, Luce JM, et al. Selective delivery of pentamidine to the lung by aerosol. Am Rev Respir Dis 1988; 137: 477–8.
- 9 Conte JE, Golden JA. Concentrations of aerosolized pentamidine in bronchoalveolar lavage, systemic absorption, and excretion. Antimicrob Agents Chemother 1988; 32: 1490–3.
- 10 Bressolle F., de la Coussaye JE, Ayoub R., et al. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992; 36: 1404–11.
- 11 LeConte P., Potel G., Peltier P., et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993; 147: 1279–82.
- 12 O'Riordan TG, Baughman RP, Dohn MN, Smaldone GC. Lobar pentamidine levels and Pneumocystis carinii pneumonia following aerosolized pentamidine. Chest 1994; 105: 53–6.
- 13 Mukhopadhyay S., Staddon GE, Eastman C., Palmer M., Davies Rhys E, Carswell F.. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Respir Med 1994; 88: 203–11.
- 14 Lake KB, Van Dyke JJ, Rumsfeld JA. Combined topical pulmonary and systemic gentamicin: the question of safety. Chest 1975; 68: 62–4.
- 15 Girard PM, Clair B., Certain A., et al. Comparison of plasma concentration of aerosolized pentamidine in nonventilated and ventilated patients with pneumocystosis. Am Rev Respir Dis 1989; 140: 1607–10.
- 16 Cooney GF, Lum BL, Tomaselli M., Fiel SB. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharmacol 1994; 34: 255–9.
- 17 Touw DJ, Jacobs FAH, Brimicombe RW, Heijerman HGM, Bakker W., Berimer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997; 41: 184–7.
- 18 USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Ann Intern Med 1997; 10: 923–46.
- 19 Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999; 340: 23–30.
- 20 Rodriguez JL, Miller CG, DeForge LE, et al. Local production of interleukin-8 is associated with nosocomial pneumonia. J Trauma 1992; 33: 74–82.
- 21 Hsieh AHH, Bishop MJ, Kubilis PS, Newell DW, Pierson DJ. Pneumonia following closed head injury. Am Rev Respir Dis 1992; 146: 290–4.
- 22 Fagon JY, Chastre J., Hance AJ, Montravers P., Novara A., Gibert C.. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am J Med 1993; 94: 281–8.
- 23 Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129: 433–40.
- 24 Leu HS, Kaiser DL, Mori M., Woolson RF, Wenzel RP. Hospital-acquired pneumonia: attributable mortality and morbidity. Am J Epidemiol 1989; 129: 1258–67.
- 25 Fagon JY, Chastre J., Vuagnat A., Trouillet JL, Novara A., Gibert C.. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996; 275: 866–9.
- 26 Gross PS, Van Antwerpen C.. Nosocomial infections and hospital deaths: a case-control study. Am J Med 1983; 75: 658–62.
- 27 Fagon JY, Chastre J., Domart Y., et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1989; 139: 877–84.
- 28 Torres A., Aznar R., Gatell JM, et al. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 523–8.
- 29 American Academy of Pediatrics Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993; 92: 501–4.
- 30 American Academy of Pediatrics Committee on Infectious Diseases. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 1996; 97: 137–40.
- 31 Ottolini MG, Hemming VG. Prevention and treatment recommendations for respiratory syncytial virus infection: background and clinical experience 40 years after discovery. Drugs 1997; 54: 867–84.
- 32 Klastersky J., Hensgens C., Noterman J., et al. Endotracheal antibiotics for the prevention of tracheobronchial infection in tracheotomized unconscious patients: a comparative study of gentamicin and aminosidin-polymyxin B combination. Chest 1975; 68: 302–6.
- 33 Klick JM, du Moulin GC, Hedley-Whyte J., et al. Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis: effect on the frequency of pneumonia in seriously ill patients. J Clin Invest 1975; 55: 514–19.
- 34 Feeley TW, du Moulin GC, Hedley-Whyte J., et al. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med 1975; 293: 471–5.
- 35 Levine BA, Petroff PA, Slade CL, Pruitt TA. Prospective trials of dexamethasone and aerosolized gentamicin in the treatment of inhalation injury in the burned patient. J Trauma 1978; 18: 188–93.
- 36 Rathgeber J., Zielmann S., Panzer C., et al. Prevention of pneumonia by endotracheal micronebulization of tobramycin [abstr]. Anaesthesiol Intensivemed Notfallmed Schmerzther 1993; 28(1): 23–9.
- 37 Rouby JJ, Poete P., de Lassale M., et al. Prevention of gram-negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Intensive Care Med 1994; 20: 187–92.
- 38 Brown RB, Phillips D., Barker MJ, Pieczarka R., Sands M., Teres D.. Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B. Am J Infect Control 1989; 17: 121–5.
- 39 Hilf M., Yu VL, Sharp J., et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87: 540–6.
- 40 Leibovici L., Paul M., Poznanski O., et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41: 1127–3.
- 41 Pines A., Raafat H., Plucinski K.. Gentamicin and colistin in chronic purulent bronchial infections. Br Med J 1967; 2: 543–5.
- 42 Pines A., Raafat H., Siddiqui GM, et al. Treatment of severe Pseudomonas infections of the bronchi. Br Med J 1970; 1: 663–5.
- 43 Klastersky J., Geuning C., Mouawad E., et al. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 1972; 61: 117–20.
- 44 Klastersky J., Carpentier-Meunier F., Kahan-Coppens L., et al. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest 1979; 75: 586–91.
- 45 Sorensen VJ, Horst HM, Obeid FN, et al. Endotracheal aminoglycosides in gram-negative pneumonia: a preliminary report. Am Surg 1986; 52: 391–4.
- 46 Stoutenbeek CP, Van Saene HKF, Miranda DR, et al. Nosocomial gram-negative pneumonia in critically ill patients: a 3-year experience with a novel therapeutic regimen. Intensive Care Med 1986; 12: 419–23.
- 47 American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies. A consensus statement. Am J Respir Crit Care Med 1995; 153: 1711–25.
- 48 Celis R., Torres A., Gatell JM, Almela M., Rodriguez-Roisin R., Agusti-Vidal A.. Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93: 318–24.
- 49 Stillwell PC, Kearns GL, Jacobs RF. Endotracheal tobramycin in gram-negative pneumonitis. Drug Intell Clin Pharm 1988; 22: 577–81.
- 50 McCall CY, Spruill WJ, Wade WE. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonia. Ther Drug Monit 1989; 11: 692–5.
- 51 Weathers L., Riggs D., Santiero M., Weibley RE. Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 1990; 9: 220–1.
- 52 Gradon JD, Wu EH, Lutwick LI. Aerosolized vancomycin therapy facilitating nursing home placement. Ann Pharmacother 1992; 26: 209–10.
- 53 Hospital Infection Control Practices Advisory Committee. Recommendations for preventing the spread of vancomycin resistance. MMWR 1995; 44(RR-12): 1–13.
- 54 Conneally E., Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403–6.
- 55 Myers SE, Devine SM, Topper RL, et al. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992; 8: 229–33.
- 56 Hertenstein B., Kern WV, Schmeiser T., et al. Low frequency of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994; 68: 21–6.
- 57 Behre GF, Schwartz S., Lenz K., et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995; 71: 287–91.
- 58
DeLaurenzi A.,
Matteocci A.,
Lanti A.,
Pescador L.,
Blandino F.,
Papetti C..
Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: a single center experience from 1980 to 1995.
Infection
1996; 5: 361–6.
10.1007/BF01716080 Google Scholar
- 59 Reichenspurner H., Gamberg P., Nitschke M., et al. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627–8.
- 60 Erjavec Z., Woolthuis GMH, de Vries-Hospers HG, et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997; 16: 364–8.
- 61 Hughes WT, Armstrong D., Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551–73.
- 62 Link H., Vohringer HF, Wingen F., et al. Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 1993; 11: 403–6.
- 63 Purcell IF, Corris PA. Use of nebulised liposomal amphotericin B in the treatment of Aspergillus fumigatus empyema. Thorax 1995; 50: 1321–3.
- 64 Conte Dal I, Riva G., Obert R., et al. Tracheobronchial aspergillosis in a patient with AIDS treated with aerosolized amphotericin B combined with itraconazole. Mycoses 1996; 39: 371–4.
- 65 Birsan T., Taghavi S., Klepetko W.. Treatment of Aspergillus-related ulcerative tracheobronchitis in lung transplant recipients [letter]. J Heart Lung Transplant 1998; 17: 437–8.
- 66 Moe AA, Hardy WD. Pneumocystis carinii infection in the HIV-seropositive patient. Infect Dis Clin North Am 1994; 8: 331–64.
- 67 Montgomery BA, Feigal DW, Sattler F., et al. Pentamidine aerosol versus trimethoprim-sulfamethoxazole for Pneumocystis carinii in acquired immune deficiency syndrome. Am J Respir Crit Care Med 1995; 151: 1068–74.
- 68 Hoo Soo GW, Mohsenifar Z., Meyer RD. Inhaled or intravenous pentamidine therapy for Pneumocystis carinii pneumonia in AIDS: a randomized trial. Ann Intern Med 1990; 113: 195–202.
- 69 Monk JP, Benfield P.. Inhaled pentamidine: an overview of its pharmacological properties and a review of its therapeutic use in Pneumocystis carinii pneumonia. Drugs 1990; 39: 741–56.
- 70 Sattler RF, Feinberg J.. New developments in the treatment of Pneumocystis carinii pneumonia. Chest 1992; 101: 451–7.
- 71 Montgomery BA, Luce JM, Turner J., et al. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 1987; 2: 480–2.
- 72 Conte JE, Hollander H., Golden JA. Inhaled or reduced-dose intravenous pentamidine for Pneumocystis carinii pneumonia: a pilot study. Ann Intern Med 1987; 107: 495–8.
- 73
Girard PM,
Couderc LJ,
Farinotti R., et al.
Ultrasonic nebulised pentamidine for Pneumocystis pneumonia [letter].
Lancet
1988; 2: 1165.
10.1016/S0140-6736(88)91978-2 Google Scholar
- 74
Godfrey-Faussett P.,
Miller RF,
Semple SJG.
Nebulised pentamidine [letter].
Lancet
1988; 2: 645–6.
10.1016/S0140-6736(88)91441-9 Google Scholar
- 75 Montgomery BA, Debs RJ, Luce JM, Corkery KJ, Turner J., Hopewell PC. Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia. Chest 1989; 95: 747–50.
- 76 Miller RF, Godfrey-Faussett P., Semple SJG. Nebulised pentamidine as treatment for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Thorax 1989; 44: 565–9.
- 77 Weinberg A., Dantonio SA, Duarte MIS, Pedreira WE, Barone AA, Ishioka S.. Aerosolised pentamidine for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Rev Inst Med Trop Sao Paulo 1990; 32: 289–95.
- 78 Conte JE, Chernoff D., Feigal DW, Joseph P., McDonald C., Golden JA. Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS: a randomized trial. Ann Intern Med 1990; 113: 203–9.
- 79 Flamholc L., Haidl S., Westin E., Prellner T.. Short course of aerosol pentamidine as treatment of Pneumocystis carinii pneumonia in AIDS. Scand J Infect Dis 1991; 23: 293–8.
- 80 Korraa H., Saadeh C.. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole. South Med J 1996; 89: 272–7.
- 81 National Institutes of Health—University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1500–4.
- 82 Toso C., Williams DM, Noone PG. Inhaled antibiotics in cystic fibrosis: a review. Ann Pharmacother 1996; 30: 840–50.
- 83 Stephens D., Garey N., Isles A., Levison H., Gold R.. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis 1983; 2: 209–11.
- 84 Schaad UB, Wedgwood-Krucko J., Suter S., et al. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987; 111: 599–605.
- 85 Lifschitz MI, Denning CR. Safety of kanamycin aerosol. Clin Pharmacol Ther 1970; 12: 91–5.
- 86 Dickie KJ, de Groot WJ. Ventilatory effects of aerosolized kanamycin and polymyxin. Chest 1973; 63: 694–7.
- 87 McSharry RJ, Kirsch CM, Jensen WA, et al. Prophylaxis of aerosolized pentamidine-induced bronchospasm: a symptom based approach. Am J Med Sci 1993; 306: 20–2.
- 88 O'Doherty MJ, Thomas SHL, Gibb D., et al. Lung deposition of nebulised pentamidine in children. Thorax 1993; 48: 220–6.
- 89 Thomas SHL, O'Doherty MJ, Page CJ, Treacher DF, Nunan TO. Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am Rev Respir Dis 1993; 148: 872–7.
- 90 Baskin MI, Abd AG, Ilowite JS. Regional deposition of aerosolized pentamidine: effects of body position and breathing pattern. Ann Intern Med 1990; 113: 677–83.
- 91 DuBois J., Bartter T., Gryn J., Pratter MR. The physiologic effects of inhaled amphotericin B. Chest 1995; 108: 750–3.
- 92 Quieffin J., Hunter J., Schechter MT, et al. Aerosol pentamidine-induced bronchoconstriction: predictive factors and preventive therapy. Chest 1991; 100: 624–7.
- 93 Katzman M., Meade W., Iglar K., Rachlis A., Berger P., Chan CK. High frequency of bronchospasm with regular administration of aerosolized pentamidine. Chest 1992; 101: 79–81.
- 94 Marschke G., Sarauw A.. Danger of polymyxin B inhalation [letter]. Ann Intern Med 1971; 74: 296–7.
- 95 Ilowite JS, Baskin MI, Sheetz MS, Abd AG. Delivered dose and regional distribution of aerosolized pentamidine using different delivery systems. Chest 1991; 99: 1139–44.
- 96 Zernikow B., Fleischhack G., Hasan C., Bode U.. Cyanotic Raynaud's phenomenon with conventional but not with liposomal amphotericin B: three case reports. Mycoses 1997; 40: 359–61.
- 97 Dally MB, Kurrle S., Breslin ABX. Ventilatory effects of aerosol gentamicin. Thorax 1978; 33: 54–6.
- 98 Chua HL, Walker SL, LeSouef PN, Sly PD. Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction. Pediatr Pulmonol 1993; 16: 311–15.
- 99 Eschenbacher WL, Boushey HA, Sheppard D.. Alterations in osmolarity of inhaled aerosols cause bronchoconstriction and cough, and absence of a premeant anion causes cough alone. Am Rev Respir Dis 1984; 129: 211–15.
- 100 Godden DJ, Borland C., Lowry R., Higenbottam TW. Chemical specificity of coughing in man. Clin Sci 1986; 70: 301–6.
- 101 Lowry RH, Wood AM, Higenbottam TW. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers. Clin Sci 1988; 74: 373–6.
- 102 Chua HL, Collis GG, LeSouef PN. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J 1990; 3: 1114–16.
- 103 Desager KN, Van Bever HP, Stevens WJ. Osmolality and pH of anti-asthmatic drug solutions. Agents Actions 1990; 31: 225–8.
- 104 Dodd MI, Abbott J., Maddison J., Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997; 52: 656–8.
- 105 Miszkiel KA, Beasley R., Rafferty P., Holgate ST. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma. Br J Clin Pharmacol 1988; 25: 157–63.
- 106 Miszkiel KA, Beasley R., Holgate ST. The influence of ipratroprium bromide and sodium cromoglycate on benzalkonium chloride-induced bronchoconstriction in asthma. Br J Clin Pharmacol 1988; 26: 295–301.
- 107 Downes H., Hirshman CA. Calcium chelators increase airway responsiveness. J Appl Physiol 1985; 59: 92–5.
- 108 O'Doherty MJ, Thomas SHL. Nebuliser therapy in the intensive care unit. Thorax 1997; 52(suppl 2): S56–9.
- 109 Pitchford KC, Corey M., Highsmith AK, et al. Pseudomonas species contamination of cystic fibrosis patients' home inhalation equipment. J Pediatr 1987; 111: 212–16.
- 110 Beasley R., Rafferty P., Holgate ST. Adverse reactions to the non-drug constituents of nebuliser solutions. Br J Clin Pharmacol 1988; 25: 283–7.
- 111 Balmes JR, Estacio PL, Quinlan P., Kelly T., Corkery K., Blanc P.. Respiratory effects of occupational exposure to aerosolized pentamidine. J Emerg Med 1995; 37: 145–50.
- 112 Kacmarek RM. Care-giver protection from exposure to aerosolized pharmacologic agents: is it necessary? [editorial]. Chest 1991; 100: 1104–5.
- 113 McDiarmid MA, Fujikawa J., Schaefer J., Weinmann G., Chaisson FE, Hudson CA. Health effects and exposure assessment of aerosolized pentamidine handlers. Chest 1993; 104: 382–5.
- 114 Stanbury M., Gatti E., Sololowski JW. Reactive airways dysfunction syndrome in a nurse exposed to pentamidine [letter]. J Emerg Med 1996; 38: 330–1.
- 115 Dooley SE Jr, Castro KG, Hutton MD, et al. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR 1990; 39(RR-17): 1–29.
- 116 Consensus Conference on Aerosol Delivery. Aerosol consensus statement. Chest 1991; 100: 1106–9.
- 117 O'Callaghan C., Barry PW. The science of nebulised drug delivery. Thorax 1997; 52(suppl 2): S31–44.
- 118 Waldman DL, Weber DA, Oberdorster G., et al. Chemical breakdown of technetium-99m DTPA during nebulization. J Nucl Med 1987; 28: 378–82.
- 119 O'Riordan TG, Palmer LB, Smaldone GC. Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery. Am J Respir Crit Care Med 1994; 149: 214–19.
- 120 Smaldone GC, Fuhrer J., Steigbigel RT, McPeck M.. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1991; 143: 727–37.
- 121 British Thoracic Society Nebulizer Project Group. Current best practice for nebuliser treatment. Thorax 1997; 52(suppl 2): S1–106.
- 122 MacIntyre NR, Silver RM, Miller CW, Schuler F., Coleman RE. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med 1985; 13: 81–4.
- 123 Flavin M., MacDonald M., Dolovich M., Eng P., Coates G., O'Brodovich H.. Aerosol delivery to the rabbit lung with an infant ventilator. Pediatr Pulmonol 1986; 2: 35–9.
- 124 Cameron D., Clay M., Silverman M.. Evaluation of nebulizers for use in neonatal ventilator circuits. Crit Care Med 1990; 18: 866–70.
- 125 O'Riordan TG, Greco MJ, Perry RJ, Smaldone GC. Nebulizer function during mechanical ventilation. Am Rev Respir Dis 1992; 145: 1117–22.
- 126
Weber A.,
Morlin G.,
Cohen M.,
Williams-Warren J.,
Ramsey B.,
Smith A..
Effect of nebulizer type and antibiotic concentration on device performance.
Pediatr Pulmonol
1997; 23: 249–60.
10.1002/(SICI)1099-0496(199704)23:4<249::AID-PPUL2>3.0.CO;2-H CASPubMedWeb of Science®Google Scholar
- 127 McPeck M., O'Riordan TG, Smaldone GC. Choice of mechanical ventilator: influence on nebulizer performance. Respir Care 1993; 38(8): 887–95.
- 128 Hess D., Horney D., Snyder T.. Medication-delivery performance of eight small-volume, hand-held nebulizers: effects of diluent volume, gas flowrate, and nebulizer model. Respir Care 1989; 34: 717–23.
- 129 Kim CS, Eldrige MA, Sackner MA. Delivery efficiency of aerosols in intubated subjects [abstr]. Am Rev Respir Dis 1984; 129: A110.
- 130 Hughes JM, Saez J.. Effects of nebulizer mode and position in a mechanical ventilator circuit on dose efficiency. Respir Care 1987; 32: 1131–5.
- 131 Fuller HD, Dolovich MB, Chambers C., Newhouse MT. Aerosol delivery during mechanical ventilation: a predictive in-vitro lung model. J Aerosol Med 1992; 5: 251–9.
- 132 O'Doherty MJ, Thomas SHL, Page CJ, Treacher DF, Nunan TO. Delivery of a nebulized aerosol to a lung model during mechanical ventilation: effect of ventilator settings and nebulizer type, position, and volume of fill. Am Rev Respir Dis 1992; 146: 383–8.
- 133 Newman SP, Fellow PGD, Clay MM, Clarke SW. Evaluation of jet nebulisers for use with gentamicin solution. Thorax 1985; 40: 671–6.
- 134 Harvey CJ, O'Doherty MJ, Page CJ, Thomas SHL, Nunan TO, Treacher DF. Effect of a spacer on pulmonary aerosol deposition from a jet nebuliser during mechanical ventilation. Thorax 1995; 50: 50–3.
- 135
Smaldone GC,
Perry RJ,
Deutcsh DG.
Characteristics of nebulizers used in the treatment of AIDS-related pneumonia.
J Aerosol Med
1988; 1: 113–26.
10.1089/jam.1988.1.113 Google Scholar
- 136 Smith D., Erskine D., Steele J., Hills D., Gazzard B.. Comparison of nebuliser efficiency for aerosolizing pentamidine. J Pharm Pharmacol 1992; 44: 7–9.
- 137 Diot P., Rivoire B., Le Pape A., et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995; 8: 1263–8.
- 138 Faurisson F., Dessanges JF, Grimfeld A., et al. Nebulizer performance: AFLM study. Respiration 1995; 62(suppl 1): 13–18.
- 139 Heyder J., Gebhart J., Rudolf G., Schiller CF, Stahlhofen W.. Deposition of particles in the human respiratory tract in the size range 0.005–15 μm. J Aerosol Sci 1986; 17: 811–25.
- 140 Ahrens RC, Ries RA, Popendorf W., Wiese JA. The delivery of therapeutic aerosols through endotracheal tubes. Pediatr Pulmonol 1986; 2: 19–26.